NEW YORK (GenomeWeb) – Nuclea Biotechnologies said today that it is partnering with the Institut de recherches cliniques de Montréal (IRCM) to validate mass spec assays for insulin, proinsulin, and c-peptide.
Under the partnership the two companies will run the assays on clinical sample cohorts at both Nuclea and IRCM's facilities to test the precision, sensitivity, and reproducibility of the assays.
Nuclea plans to launch the assays commercially later this year for assessing the risk and progression of type 2 diabetes.
Based inMassachusetts, Nuclea develops diagnostic tests for breast, prostate, and other cancers, as well as for diabetes and other chronic ailments.
“Validation of these assays across two different laboratories will demonstrate high value for this new technology in clinical and research environments,” Beniot Coulombe, director of the Translational Proteomics research unit and the Proteomics Discovery Platform at IRCM, said in a statement.
Financial and other terms of the agreement were not disclosed.